Showing 1 posts of 1 posts found.

Merck building

Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments

March 1, 2021
Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant

German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …

Latest content